Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Trial sponsor
Caelum Biosciences, Inc.
Scientific Title
A Phase 3, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL-101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment in Plasma Cell Dyscrasia Treatment Naïve Patients With Mayo Stage IIIb AL Amyloidosis